1. Penpulimab and lenalidomide in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx regimen) is safe, tolerable, and shows antitumour activity ...
1. In pretreated patients with nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML), nearly half of patients treated with revumenib showed ...
Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade ...
1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% ...
1. High genetic risk participants with chronic lymphocytic leukemia (CLL) taking venetoclax in addition to ibrutinib achieved high rates of ...
